Main Article Content


Background: Diabetes Mellitus (DM), which results from insulin resistance, is closely linked to long-term damage to pancreatic beta cells, organ dysfunction, and organ failure, particularly in the eyes, kidneys, nerves, heart, and blood vessels. The development of the ATC/DDD system is necessary to increase global drug knowledge, ensure equitable drug availability, and promote responsible drug use. Objectives: This study aimed to identify data on patient characteristics and oral anti-diabetic drugs and insulin using the ATC/DDD and DU90% methods. Material and Methods: This study was a cross-sectional evaluation of oral anti-diabetic medications and insulin using the ATC/DDD method and DU90% at the Bala Keselamatan Bokor Turen Hospital from January to December 2022. The inclusion criteria were patients diagnosed with type 1 or type 2 diabetes mellitus, with or without comorbidities, who were treated with oral anti-diabetic medications and a combination of insulin and oral medications. In the present study, the incomplete medical record data served as the exclusion criteria. The sample for this investigation consisted of 238 patients selected using the complete sampling technique. Results: Most patients who used oral anti-diabetic medications and insulin were between the ages of 46 and 65 (71.34%), were female (73.2%), had standard body mass index (BMIs between 18.5 and 25), and had diagnoses of DM + HT (20.73%) and Type II DM (18.29%). Glulisin was the most used anti-diabetic drug, accounting for 589 DDD/100 days of hospitalization, and DU90% was 21.39%. Conclusion: Glulisin is the most frequently prescribed anti-diabetic medication at Bokor Turen Hospital.


Antidiabetic Oral and Insulin Diabetes Mellitus ATC/DDD DU 90%

Article Details

How to Cite
Hendra, G. A., Nugraha, D. P., & Krisdia, T. A. (2024). Evaluation of Anti-diabetic Drugs using ATC/DDD and DU90% Methods in Diabetes Mellitus Patients: Evaluasi Obat Antidiabetik menggunakan Metode ATC/DDD dan DU90% pada Pasien Diabetes Melitus. Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal), 10(1), 96-106.


  1. Ali, M.D., Ahmad A., Banu N., Patel M., Gohsn S.A., I Z.E. (2022) 'Evaluation of drug utilization pattern and cost associated with diabetes mellitusType two management in Saudi Arabia', Brazilian Journal of Pharmaceutical Sciences, 58, p. E20681. Available at:
  2. Almasdy, D., Sari D.P., Suhatri S., Darwin D., Kurniasih N. (2015) 'Evaluation of the Use of Anti-diabetic Drugs in Type-2 Diabetes Mellitus Patients in a Government Hospital of Padang City – West Sumatra', Journal of Pharmaceutical & Clinical Science, 2(1), p. 104. Available at:
  3. Chrisnawati, H. (30 January 2024). Citing Internet sources URL
  4. Czech, M., Rdzanek, E., Pawȩska, J., Adamowicz-Sidor, O., Niewada, M., & Jakubczyk, M. (2015). Drug-related risk of severe hypoglycaemia in observational studies: A systematic review and meta-analysis. BMC Endocrine Disorders, 15(1).
  5. DiPiro, J.T. (ed.) (2020) Pharmacotherapy: a pathophysiologic approach. Eleventh edition. New York: McGraw Hill Medical.
  6. Gerstein, H., Bosch, J., Dagenais, G. R., Diaz, R., Jung, H., Maggioni, A. P., … Probstfield, J. (2012). Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine, 367(4), 319–328.
  7. Okoro, R.N., Nmeka, C. and Erah, P.O. (2018) 'Utilization study of antidiabetes medicines at a tertiary care hospital in Nigeria', Future Journal of Pharmaceutical Sciences, 4(2), pp. 109–115. Available at:
  8. Joseph, J. J., & Donner, T. W. (2015). Long-term insulin glargine therapy in type 2 diabetes mellitus: A focus on cardiovascular outcomes. Vascular Health and Risk Management, 11, 107–116.
  9. Pitasari, N.W.N., Andayani, T.M. and Wijayanti, T. (2022) 'Evaluation of the Use of Antidiabetic Drugs in Patients of Back-Referral Program at the Demak District Pharmacy', Journal of Management and Pharmacy Practice, 12(2), p. 125. Available at:
  10. Pollock, R.F., Valentine W.J., Pilgaard T., Nishimura H. (2011) 'The cost-effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective', Journal of Medical Economics, 14(1), pp. 36–46. Available at:
  11. Ray, S., Ganguly K., Rao M.S., Sinha S., Kumar Y.S., Manchanda S.C., Sharma R.K., Mehta A., Sawhney JPS., Prasad A., Talathi M. (2022) 'Usage Pattern of Glimepiride/Metformin Fixed-dose Combination in Type 2 Diabetes Patients with CVD or at Risk of CVD: An Experience in Indian Setting', Asian Journal of Diabetology, 23(2), pp. 13–19.
  12. RI, K. (2017) 'Technical Guidelines for Evaluation of Drug Use in Health Facilities'.
  13. Soelistijo, S.A., Suastika K., Lindarto D., Decroli E., Permana H., Sucipto KW., Kusnadi Y., Budiman., Ikhsan R., Sasiarini L., Sanusi H., Nugroho HS KH., Susanto H. (2021) 'Guidelines for the management and prevention of adult type 2 diabetes mellitus in INDONESIA - 2021', PB. PERKENI, p. 119.
  14. Svensson, A.-M. Miftaraj M., Franzen S., Eliasson B. (2017) 'Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study', Clinical Diabetes and Endocrinology, 3(1), p. 5. Available at:
  15. Tahar, N., Febriyanti A.P., Wahyuddin M., Hasti S.A. (2020). Evaluation of The Use of Oral Anti-Diabetic Drugs In Type 2 Diabetes Mellitus Patients Using ATC/DDD and DU 90% Methods. The 2nd Alauddin Pharmaceutical Conference and Expo (ALPHA-C) 2020 [Preprint]. Available at:
  16. WHO (2023) Diabetes. Available at: (Accessed: September 21, 2023).